What is the 13F Pro Quality Score for PCRX?

13F Pro ranks Pacira BioSciences, Inc. (PCRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PCRX's current score at https://13fpro.ai/research/PCRX (free sign-up required for the full ranking).

Which hedge funds own the most PCRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PCRX include BlackRock,, LINDEN ADVISORS, Context Capital Management,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PCRX as soon as new 13F filings post.

Where does 13F Pro source PCRX data?

All Pacira BioSciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Pacira BioSciences, Inc. files with the SEC under CIK 1396814. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PCRX in?

Pacira BioSciences, Inc. (PCRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PCRX research updated on 13F Pro?

PCRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Pacira BioSciences, Inc.(PCRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1396814 PCRX stock profile & AI dashboard →

13F Pro Quality Score

48.0/100

Rank #1,580 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

45.2/100

Profitability

58.4/100

Balance Sheet

40.5/100

Earnings Quality

6.8/100

Free Cash Flow

74.5/100

Institutional Flow

45.5/100

Revenue Scale

42.7/100

Dilution Risk

19.8/100

PCRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Pacira BioSciences, Inc. (PCRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PCRX at 48.0/100 on a 32-signal composite quality model, placing it at rank #1,580 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (6.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 19.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Pacira BioSciences, Inc. reports quarterly revenue of $177.4M, net income of $2.9M, an operating margin of 3.9%. Top institutional holders of PCRX by reported 13-F value include BlackRock,, LINDEN ADVISORS, Context Capital Management,, based on the most recent SEC filings. PCRX trades on the Nasdaq exchange and files with the SEC under CIK 1396814. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pacira BioSciences, Inc. directly from SEC EDGAR. Pacira BioSciences, Inc.'s 13F Pro composite quality score has ranged between 8 and 66 since 2021, currently 48.0 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Pacira BioSciences, Inc.

Quirks, history, and lore behind PCRX — the kind of stuff that makes a stock memorable.

1
The Basics
A specialty pharmaceutical company · small-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with most of that driven by a single flagship product — a risky but familiar biotech business model.
3
The History
Founded in the early 2000s, it was built around a mission to transform post-surgical pain management and reduce dependence on opioids after procedures.
4
The Secret
Its core technology is a liposomal drug-delivery system that slowly releases a local anesthetic — think a time-release capsule, but injected directly at the surgical site.
5
The Lore
It has positioned itself as a genuine weapon in the fight against the opioid crisis, arguing that better non-opioid nerve blocks mean fewer patients ever need a single Vicodin after surgery.
6
The Giveaway
Its flagship product, EXPAREL, is a long-acting bupivacaine injectable that surgeons use to numb surgical sites for up to 72 hours — keeping patients off opioids one procedure at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$177.4M

Net Income

Q1 2026

$2.9M

Free Cash Flow

Q1 2026

$23.0M

Operating Margin

Q1 2026

3.9%

ROIC

Q1 2026

0.7%

D/E Ratio

Q1 2026

0.56

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.2% YoY

$675.0MFY 2023

FY18 $337.3MFY21 $541.5MFY22 $666.8MFY23 $675.0M

Net Income

+163.9% YoY

$42.0MFY 2023

FY18 $-471.0KFY21 $42.0MFY22 $15.9MFY23 $42.0M

Operating Income

+46.1% YoY

$87.7MFY 2023

FY18 $15.9MFY21 $89.9MFY22 $60.0MFY23 $87.7M

EPS (Diluted)

+161.8% YoY

$0.89FY 2023

FY18 $-0.01FY21 $0.92FY22 $0.34FY23 $0.89

Total Assets

-6.4% YoY

$1.57BFY 2023

FY18 $689.4MFY21 $2.08BFY22 $1.68BFY23 $1.57B

Total Debt

-24.2% YoY

$522.4MFY 2023

FY18 —FY21 —FY22 $689.5MFY23 $522.4M

Op. Cash Flow

+6.5% YoY

$154.6MFY 2023

FY18 $48.9MFY21 $125.7MFY22 $145.3MFY23 $154.6M

Metric	FY 2023	FY 2022	FY 2021	FY 2018	FY 2017	FY 2016
Revenue	$675.0M +1.2%	$666.8M +23.1%	$541.5M +60.6%	$337.3M +17.7%	$286.6M +3.7%	$276.4M
Net Income	$42.0M +163.9%	$15.9M -62.1%	$42.0M +9017.2%	$-471.0K +98.9%	$-42.6M -12.3%	$-37.9M
Operating Income	$87.7M +46.1%	$60.0M -33.3%	$89.9M +465.0%	$15.9M +163.8%	$-24.9M +22.1%	$-32.0M
EPS (Diluted)	$0.89 +161.8%	$0.34 -63.0%	$0.92 +9300.0%	$-0.01 +99.1%	$-1.07 -4.9%	$-1.02
Total Assets	$1.57B -6.4%	$1.68B -19.0%	$2.08B +201.1%	$689.4M +9.7%	$628.4M +60.5%	$391.5M
Total Debt	$522.4M -24.2%	$689.5M	—	—	—	$227.3M
Operating Cash Flow	$154.6M +6.5%	$145.3M +15.6%	$125.7M +157.2%	$48.9M +174.8%	$17.8M	—

Get alerted when PCRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Pacira BioSciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PCRX

BlackRock, Inc.
$152.2M6,735,343 sh
LINDEN ADVISORS LP
$117.8M121,495,000 sh
Context Capital Management, LLC
$78.5M81,306,000 sh
Doma Perpetual Capital Management LLC
$62.8M2,777,794 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$56.5M2,501,286 sh
DIMENSIONAL FUND ADVISORS LP
$46.6M2,060,597 sh
D. E. Shaw & Co., Inc.
$44.8M1,982,724 sh
STATE STREET CORP
$43.4M1,919,610 sh
RENAISSANCE TECHNOLOGIES LLC
$41.3M1,825,501 sh
VANGUARD CAPITAL MANAGEMENT LLC
$40.3M1,784,049 sh

Fund	Value	Shares
BlackRock, Inc.	$152.2M	6,735,343
LINDEN ADVISORS LP	$117.8M	121,495,000
Context Capital Management, LLC	$78.5M	81,306,000
Doma Perpetual Capital Management LLC	$62.8M	2,777,794
VANGUARD PORTFOLIO MANAGEMENT LLC	$56.5M	2,501,286
DIMENSIONAL FUND ADVISORS LP	$46.6M	2,060,597
D. E. Shaw & Co., Inc.	$44.8M	1,982,724
STATE STREET CORP	$43.4M	1,919,610
RENAISSANCE TECHNOLOGIES LLC	$41.3M	1,825,501
VANGUARD CAPITAL MANAGEMENT LLC	$40.3M	1,784,049

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PCRX on your watchlist

Track score changes the day Pacira BioSciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PCRX a good stock to buy?

13F Pro's AI-powered analysis of Pacira BioSciences, Inc. (PCRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PCRX are available on the PCRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PCRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PCRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pacira BioSciences, Inc.'s investment landscape.